Detalles de la búsqueda
1.
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort.
Hepatology
; 66(6): 1814-1825, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28741307
2.
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?
Liver Int
; 38(12): 2190-2198, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29900654
3.
Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Lancet Reg Health Eur
; 31: 100684, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37547273
4.
Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring.
Antibiotics (Basel)
; 11(8)2022 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-35892386
5.
Psychiatric Disorders after Switching to Dolutegravir: A Case Report of a 59-Year-Old Virosuppressed HIV-1 Positive Woman.
Case Rep Infect Dis
; 2020: 9708913, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32351747
6.
In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
Front Cell Infect Microbiol
; 9: 190, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31259160
7.
Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy.
Antiviral Res
; 96(3): 422-9, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23026293
Resultados
1 -
7
de 7
1
Próxima >
>>